Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Zyrtec-D promotions

Executive Summary

Professional sales aid and product website for Zyrtec-D (certirizine/pseudoephedrine) fail to include contraindications and warnings regarding the antihistamine's pseudoephedrine component, April 22 1FDA ad division letter says. Associate Commissioner Peter Pitts recently pointed to Pfizer's website as a model for internet promotion (2"The Pink Sheet" April 5, 2004, p. 18)...

You may also be interested in...



Decline In Ad Letters Does Not Signal Leniency By FDA, Agency Says

Although FDA is issuing fewer warning letters, those issued are more likely to signal a potential enforcement action, FDA Associate Commissioner Peter Pitts suggested during the DTC National Conference & Expo in Boston March 30

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.

Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

UsernamePublicRestriction

Register

PS043884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel